Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
JMIR Research Protocols|March 30, 2023
Digital Outcome Measurement to Improve Care for Patients With Immune-Mediated Inflammatory Diseases: Protocol for the IMID RegistryAgnes E M Looijen, Reinier C A van Linschoten, Jan-Dietert Brugma, et al.
The British Journal of Dermatology|September 9, 2024
A practical guide to using oral Janus kinase inhibitors for atopic dermatitis from the International Eczema CouncilCarter Haag, Andrew Alexis, Valeria Aoki, et al.
Allergy|March 5, 2024
Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after mRNA vaccinationAnika M Valk, Jim B D Keijser, Koos P J van Dam, et al.
Allergy|August 5, 2024
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declarationClaudia Traidl-Hoffmann, Jamie Afghani, Cezmi A Akdis, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
The Journal of Dermatology|February 14, 2025
Impact of COVID-19 disease and vaccination on dermatological immune-mediated inflammatory diseases atopic dermatitis, psoriasis, and vitiligo: a Target2B! substudyNicoline F van Buchem-Post, Wouter Ouwerkerk, Eileen W Stalman, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
The Lancet. Rheumatology|May 9, 2022
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studiesLaura Boekel, Eileen W Stalman, Luuk Wieske, et al.
Pageof 2